Parkinson’s disease therapeutic market

Jan 06, 2025

What is Parkinson's? Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement and coordination. It is a condition caused by the gradual loss of dopamine-producing neurons in the brain, leading to symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and p...

Dec 24, 2024

Parkinson’s disease is a complex and progressive neurodegenerative disorder that affects millions worldwide, with its prevalence expected to rise due to aging populations and environmental factors. Characterized by a gradual decline in motor and non-motor functions, the disease significantly impacts the quality of ...

Dec 24, 2024

Parkinson's disease is a progressive neurological disorder that affects movement control. It occurs when dopamine-producing neurons in the brain are damaged or die. The exact cause of Parkinson's disease is still unknown, but symptoms include tremors, stiffness, and difficulty with coordination. Parkinson's disease...

Nov 18, 2024

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...

Dec 30, 2022

Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...

Nov 15, 2022

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Jan 26, 2021

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Jul 09, 2019

NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer...

Apr 29, 2019

Parkinson's Awareness Month April marks Parkinson's Awareness Month, is an occasion to spread awareness about Parkinson’s. Not the early signs as they are more than just any tremor! Parkinson’s changes everything. Over 10 Million people are living with Parkinson’s worldwide yet the condition remains a mystery. ...